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Abstract 
Background: Although the overall outcome of cerebral vein and dural sinus thrombosis 
(CVT) is good, about 25% of patients develop complications, and mortality rate is 3-
15%. Identification of prognostic factors is crucial for selecting the proper treatment 
for each case (aggressive versus conservative). A risk score comprising six clinical 
variables with different hazard ratios was proposed by Ferro et al, 2009, to predict CVT 
outcome. Aims: to evaluate the ability of this score in predicting the prognosis of our 
CVT patients. Methods: retrospective analysis of consecutive adult patients admitted 
with CVT from 2006 to 2012 in our tertiary hospital, with at least 6 months of follow 
up. The prognostic variables and score were analysed and compared with outcome at 
six months, using a simplified regression model (R>0.5 suggesting a strong 
relationship). Results: 59 patients; 83.1% females; mean age: 40.1 years-old. The value 
of R between the result of the weighted risk scale and outcome was 0.344. When the 6 
variables were combined but not weighted, and compared with outcome, R value was 
0.548. For the combination of “malignancy”, “intracranial haemorrhage on admission” 
and “thrombosis of deep venous system” the R value was 0.523. There was no 
significant correlation between other variables independently or combined. 
Conclusions: In our population, the proposed risk score did not show a strong 
correlation with prognosis. However the combination of intracranial haemorrhage, 
malignancy and thrombosis of deep venous system had a stronger correlation with 
outcome, being probably the most important predictive factors in clinical practice. 
 
 
  
Introduction 
Cerebral venous and sinus thrombosis (CVT) is an uncommon form of cerebrovascular 
disease, representing only 0.5 to 1% of all strokes[1], with an incidence estimated at 2 
to 5 per 1 million[2]. It affects mostly young people, although it can happen at any 
age[3-5], and women are more likely to suffer from CVT, with a female/male ratio of 3 
to 1[4]. 
CVT diagnosis can be difficult, not only because of the low incidence, but also because 
it may present with a wide variety of symptoms, which may be categorized in two main 
syndromes: signs of acute focal brain injury due to venous infarct, edema or 
hemorrhage; or more insidious symptoms of increased intracranial pressure. The 
diagnosis is usually based on magnetic resonance imaging with magnetic resonance 
venography, although contrast-enhanced computed tomography or CT venography 
may also help in the diagnostic process[6].  
The basis of the treatment of an acute CVT is anticoagulation, with unfractionated 
heparin or low molecular weight heparin[7]. Some complications demand specific 
treatment. In case of seizures, antiepileptic drugs are effective[8]. Intracranial 
hypertension may be treated with acetazolamide[9], mannitol along with 
hyperventilation[10, 11], serial lumbar punctures or lumboperitoneal shunt[12]  
In more serious cases of CVT, more aggressive measures may be necessary. In the 
presence of clinical deterioration or elevated intracranial pressure, local thrombolytic 
therapy may improve recanalization [13]. Descompressive craniectomy is sometimes 
used in cases of lesions producing mass-effect and clinical deterioration, with good 
rates of clinical recovery[14].  
In order to prevent CVT recurrence, some patients may have indication for long term 
anticoagulation, depending on the risk factors, namely the presence of inherited or 
acquired thrombophilia. 
Although most patients have a good prognosis, 5% die in the acute phase [15, 16]. In 
long term follow up, mortality and morbidity rates are about 15%[4, 17]. In the acute 
phase, the main complications are hydrocephalus, intracranial hypertension and 
seizures including status epilepticus[6], and patients die primarily due to neurological 
complications, being the main cause of early mortality transtentorial herniation[15]. 
Late possible complications are recurrent CVT, chronic headaches, epilepsy, visual loss 
and the development of dural arteriovenous fistula[6]. Late deaths are mainly due to 
underlying conditions, like malignancy[6]. Early diagnosis and treatment are essential 
to decrease the risk of permanent neurological impairment and death. Therefore it is 
very important to identify patients with worse prognosis, so that they can be provided 
with close vigilance and more aggressive treatment. On the other side, identification of 
patients with a better prognosis is relevant so that more aggressive diagnostic and 
therapeutic procedures are avoided. 
Some poor prognostic factors have been consistently appointed: depressed 
consciousness or coma, mental status disturbance, thrombosis of the deep venous 
system, right hemisphere hemorrhage, posterior fossa lesion [15], involvement of the 
straight sinus [18], neurological deficit and severity, encephalopathy [19], venous 
infarction, the existence of an underlying coagulopathy or hereditary thrombophilia 
[20], hemiparesis,  intracranial hemorrhage, seizures, central nervous system infection, 
any malignancy, age >37 years and male gender[4]. 
Recently, six prognostic factors related to worse outcome at six months were 
described in a sample of CVT patients. These factors are: underlying malignancy, 
presentation as coma, thrombosis of the deep venous system, presentation as mental 
status disturbance, male gender and intracranial hemorrhage[17]. These prognostic 
factors where combined in a weighted risk score, in which each variable was 
punctuated as 1 or 2 depending on the hazard ratios. Malignancy, coma and 
thrombosis of the deep venous system had a punctuation of 2 and the others 
punctuated 1. According to this risk score, if the total punctuation is greater than 2 
then the patient is considered to have a poor outcome prognosis. 
It is of a great importance to validate this score in daily practice so that it can become a 
routine tool in the evaluation of CVT patients.   
 
Aim 
The objective of this study was to test the scale in a Portuguese population of CVT 
patients, and evaluate the impact of the scale and the prognostic factors individually in 
the prediction of the outcome of our patients. 
 
Methods 
We conducted a retrospective study of adult patients with a final diagnosis of CVT 
admitted to the Neurology Department of Hospital de São João, Porto, Portugal, 
between the years of 2006 and 2012. Those without follow up at 6 months were 
excluded. Demographic, clinical, radiological, etiological and prognostic data were 
collected. Outcome was evaluated at 6 months, and classified as good when modified 
Rankin Scale (mRS) was between 0 and 2, and as bad when mRS was greater than 2. 
The presence of each one of the six risks factors previously mentioned[17] was 
evaluated and the proposed risk score was applied. The correlation of the outcome 
with the weighted risk score, as well as with each variable independently or simply 
combined was measured. The data were analyzed by using Statistical Package for the 
Social Sciences version 21 (SPSS 11.5 for Windows, Chicago, IL, USA). For continuous 
variables, means and standard deviations were calculated. For categorical variables, 
numbers and percentages for each category were tabulated. In order to assess the 
relationship of the mentioned risk factors for bad outcome with the prognosis, simple 
linear correlation was calculated between the outcome of the patients and the 
proposed variables individually or combined in the score. Statistical significance level 
was accepted as p < 0.05, and the R value was considered relevant when greater than 
0.5. 
This study was approved by the Hospital’s Ethics Committee. 
 
Results 
A total of 59 patients were included. The median age at presentation was 40.1 years 
(19-73), and 83.1% were female. 
The most common symptom at presentation was headache (table 1)(78% of patients). 
Time from symptoms’ onset to diagnosis is shown in table 2, but only 33.9% of the 
patients had symptoms for more than one week. Most of the patients (69.5%) had 
affection of multiple sinuses (table 3). The most common risk factors (table 4) were 
estrogen-containing drugs (44.1%), genetic prothrombotic conditions (42.4%) and 
acquired prothrombotic conditions (33.9%). The treatment received is described in 
table 5. Most of the patients were treated with low molecular weight heparin (49.2%) 
in the acute phase.  
Analyzing the outcome at 6 months, 8.5% of our patients had a bad outcome (mRS 
greater than 2). 
Concerning prognostic factors included in the score, 27.1% of the patients presented 
with mental status disturbance, 16.9% were male, 8.5% had intracranial hemorrhage, 
8.5% had an underlying malignancy and 5.1% had thrombosis of the deep venous 
system (table 6). None of our patients presented with coma. When we applied the 
weighted score, 8.5% of the patients had a score greater than 2, predicting a bad 
prognosis. 
In the simple linear regression between the weighted risk score and the actual 
outcome, the R value was 0.344. On the other side, analyzing all the prognostic 
variables simply combined (not weighted as in the risk score) compared with the 
outcome, the R value was 0.548.  
When the individual variables were compared with the score, only three of them were 
significantly related to the prognosis. The presence of hemorrhage at presentation, 
compared with the outcome, had an R value of 0.344, as well as the presence of a 
underlying malignancy.  When both are taken in account, the R value was 0.459. The 
combined presence of hemorrhage, malignancy and thrombosis of the deep venous 
system showed an R value of 0.523 and the other variables showed no significance 
(table 7). 
 
Discussion 
The identification of CVT patients with a worse prognosis is very important in clinical 
practice, having in mind the existence of more aggressive treatments, from which most 
patients would not obtain any additional benefit, but that can be useful in those 
patients whose clinical status is more likely to deteriorate. Many studies tried to 
identify the factors of bad prognosis, and the more consensual factors were combined 
in the score above mentioned [17], which we applied retrospectively to our 
population. According to our data, the correlation between the weighted prognostic 
risk score and the outcome was weak. On the other hand, taking in account all the 
prognostic variables proposed but not combined in the weighted score, a stronger 
correlation was found. When the variables where compared individually with the 
outcome, only three of them were significant: the presence of hemorrhage at 
presentation was the one that had a better correlation with the outcome of our 
patients, with the same R value as the whole risk score. When there was an underlying 
malignancy and the thrombosis of the deep venous system was summed to the 
presentation with hemorrhage, a higher correlation was found, although it was still not 
very strong. One of the main problems about CVT studies is the fact that its very low 
incidence makes it difficult to have big samples. Besides that, most of the patients 
have good prognosis, and the risk factors proposed in the score are not common. All 
these factors may have contributed to the weak correlation found in our study 
between the score and the prognosis.  It is also possible that our population had 
different characteristics when compared to the populations used to validate the 
original score, and the relative importance of risk factors may be different, being the 
presentation with hemorrhage, thrombosis of deep venous system and the existence 
of an underlying malignancy more important than the other variables. It is also 
possible that other risk factors not included in the primary study may be more 
relevant. The fact that this was a retrospective study may also have influenced the 
results we obtained. 
Taking into account our results, we suggest that more aggressive management 
decisions should probably be taken in CVT patients with intracranial hemorrhage, 
particularly when an underlying malignancy is present and the thrombosis occurs in 
the deep venous system.  
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Table 1: Symptoms at presentation 
Symptoms at presentation 
Prevalence (%/n) 
  Headache 
78% (46) 
  Papilledema 
30.5% (18) 
  Motor deficit 
23.7% (14) 
  Sensitive deficit 23.7% (14) 
  Acute symptomatic seizures 
22% (13) 
  Visual disturbance 
20.3% (12) 
  Aphasia 
16.9% (10) 
 
 
  
Table 2: Time from symptoms’ onset to diagnosis 
Time from symptoms’ onset to 
diagnosis 
Prevalence (%/n) 
  < 24 hours 
20.3% (12) 
  2 to 4 days 
23.7% (14) 
  5 to 7 days 
15.3% (9) 
  > 7 days 
33.9% (20) 
 Unknown 
6.8% (4) 
 
  
Table 3: Affected sinuses 
Affected sinuses Prevalence (%/n) 
  Superior sagittal 8.5%(5) 
  Sigmoid 8.3%(5) 
  Transverse 6.8%(4) 
  Cortical Veins 5.1%(3) 
  Straight 1.7%(1) 
  Combined 69.5%(41) 
 
 
  
Table 4: Risk factors 
Risk factors Prevalence (%/n) 
  Estrogen-containing drugs 44.1%(26) 
  Genetic prothrombotic factor 42.4%(25) 
  Acquired prothrombotic factor 33.9%(20) 
  Cephalic infection (otitis, mastoiditis, 
sinusitis) 
22%(12) 
  Thyroid pathology 8.5%(5) 
  Previous CVT 5.1%(3) 
  Family history of venous thrombosis or 
thrombophilia 
5.1%(3) 
  Pregnancy/puerperium 3.4%(2) 
  Systemic infection 3.4%(2) 
 
  
Table 5: Treatment 
Treatment  Prevalence (%) 
  Low molecular weight heparin 49.2%(29) 
  Non-fractionated heparin 39%(23) 
  Vitamin K antagonists 6.8%(4) 
  No treatment 5.1%(3) 
 
 
  
Table 6: Prognostic factors at admission 
Prognostic factors at admission Prevalence (%/n) 
Mental status disturbance 27.1%(16) 
Male sex 16.9%(10) 
Intracranial hemorrhage 8.5%(5) 
Malignancy 8.5%(5) 
Thrombosis of deep venous system 5.1%(3) 
Coma 0%(0) 
 
Table 7: Correlation between risk score prognostic variables and poor outcome 
 R Value 
Weighted risk score 0.344 
Score variables simply combined (not weighted) 0.548 
Malignancy 0.344 
Intracranial hemorrhage 0.344 
Thrombosis of deep venous system 0.207 
Male sex 0.025 
Mental status disturbance -0.049 
Malignancy + intracranial hemorrhage 0.459 
Malignancy + mental status disturbance + 
thrombosis of deep venous system 
0.523 
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Generally, a Panorama will be a discussion about the state of stroke in a particular 
region with an emphasis on MORE than one center, although we recognize this is 
not always possible. 
 
Text 
Typically this type of piece will have headings; however, the authors are 
encouraged to adopt their own style, please refer to previous editions of the 
International Journal of Stroke. 
 
References Please refer to references section. 
 
 
PRESENTATION OF A CLINICAL TRIAL PROTOCOL ARTICLE 
Manuscripts that incorporate clinical trial information, or subsequent reporting 
should be referenced against the CONSORT statement http://www.consort-
statement.org/. 
 
Abstract or Executive Summary 
No more that 250 words 
• Rationale 
• Aims and/or hypothesis 
• Design 
• Study outcome(s) 
• Discussion 
 
Introduction and rationale 
 
Methods 
• Design 
• Patient population - inclusion and exclusion criteria 
• Randomization 
• Treatment or intervention 
• Primary outcomes 
• Secondary outcomes 
• Data Monitoring Body 
• Sample size 
• Statistical analyses 
• Study organization and funding Discussion This section is to contain the thoughts 
and rationale behind important points of study set-up. 
 
Summary and conclusions 
 
References Please refer to references section. 
 
 
PRESENTATION OF AN ORIGINAL ARTICLE (RESEARCH ARTICLE) 
All original articles incorporating clinical trial information and subsequent 
reporting, should be referenced against the CONSORT statement 
http://www.consort-statement.org/. 
 
Abstract 
Please provide a structured abstract according to the following headings: 
• Background 
• Aims and/or hypothesis 
• Methods 
• Results 
• Conclusions 
 
Text 
Introduction 
Aims and/or hypothesis 
Methods 
Results 
Discussion 
References 
 
 
PRESENTATION OF A GUIDELINES MANUSCRIPT 
Documents should be double spaced and structured in the following order: 
 
Abstract 
Guidelines are usually a condensed interpretation of a larger paper that goes 
through an extensive process, via a committee, and other interested parties. Please 
condense your manuscript to comply with our word limit but feel free to present 
the article in the committee/interested parties style. Please provide an 
unstructured abstract. 
 
Text 
Guidelines should be structured as per the original briefs of the requesting body. 
This may vary from country to country. 
 
References Please refer to references section. 
 
 
PRESENTATION OF LETTERS TO THE EDITOR 
Letters to the Editor are published online only. Documents should be double 
spaced and structured in the following order: 
 
Text should be 250-300 words. Please refer to previous editions of IJS for example. 
 
References should be a maximum of five references. Please also refer to 
references section. 
  
REFERENCES 
 
These must be limited to the work cited in the paper and should not be a 
bibliography of the subject. Personal communications and unpublished material 
are not acceptable as references. 
 
Each reference should conform to the Vancouver style, 
(http://en.wikipedia.org/wiki/Vancouver_system) and references should be 
numbered consecutively in the order in which they are first mentioned in the text. 
 
List all authors (include all initials) when there are six or fewer; when seven or 
more, list the first three and add 'et al'. 
 
Give the title of the paper in full; the title of the journal abbreviated according to 
Index Medicus or on PubMed (if not listed by Index Medicus spell in full); the year; 
the volume number and the first and last page numbers of the article, eg. 
 
Standard journal 
Siebke H, Breivik H, et al. Survival after 40 minutes submersion without cerebral 
sequel. Lancet 1995;1:1275-7. 
 
Section of a book 
Talley NJ, O'Connor S. Clinical Examination. 5th ed. Minnesota: Churchill 
Livingstone, 2005;114-17. 
 
Chapter in a book 
Buckley WE, Nunn T. A rational response to the threat of bioterrorism. In: Plant 
GW, Blair A, Winston JH Jnr, editors. Primary care in the third millennium. 
Washington: R McGeddon Inc., 2006;457-72. 
 
Website 
Drug-interactions.com [homepage on the Internet]. Indianapolis: Indiana 
University Department of Medicine; 2003 [updated 17 May 2006; cited 30 May 
2006]. Available from: http://medicine.iupui.edu/flockhart/ 
 
We recommend the use of a tool such as EndNote or Reference Manager for 
reference management and formatting. 
 
EndNote reference styles can be searched for 
here:http://www.endnote.com/support/enstyles.asp 
 
Reference Manager reference styles can be searched for 
here:http://www.refman.com/support/rmstyles.asp 
 
 
Figures and Illustrations 
 
Illustrations are encouraged for their educational value. Diagrams, line drawings, 
photographs or fl ow charts are valuable but their use will be subject to editorial 
judgment. Photographic illustrations and diagnostic imaging media must be 
supplied in electronic form. The only acceptable format is Tiff or JPEG file, at 300 
dpi. 
 
Go to http://authorservices.wiley.com/bauthor/illustration.asp for author 
guidelines on electronic artwork. 
 
Tables must supplement the text without duplicating it. Each should be numbered, 
typed on a separate electronic sheet, and have an appropriate title, all manuscripts 
must be in basic Word format, PDF files cannot be accepted. Please do not create 
tables as a JPEG file if it can be avoided. They need to be in word format for editing 
purposes. 
Permissions 
Authors are responsible for obtaining permission to reproduce published (or 
otherwise copyright) material. A copy of the written permission(s) must be 
enclosed with the manuscript. Authors must also enclose a copy of the written 
consent of any person who can be identified in the text or illustrations. 
Disclosure of funds/ Conflicts of interests 
Authors of research papers are required to disclose any sponsorship or funding 
arrangements relating to their research and all authors should disclose any 
possible conflicts of interest. 
Editing 
All manuscripts are subject to editing for length, clarity and conformity 
with International Journal of Stroke style all content must be approved by the 
Editor-in-Chief before being sent to graphics. Any major content changes or cuts 
must be approved by the author. Word count limitations should be observed. A 
proof PDF of the final manuscript will be sent to the principal/corresponding 
author before publication and must be returned by the date requested. No 
corrections may be made after it has been returned. 
 
Early View 
International Journal of Stroke is now available via the Early View service. Early 
View articles are complete full-text articles published online in advance of their 
publication in a printed issue. Articles are therefore available as soon as they are 
ready, rather than having to wait for the next scheduled print issue. 
Early View articles are complete and final. They have been fully reviewed, revised 
and edited for publication, and the authors’ final corrections have been 
incorporated. Because they are in final form, no changes can be made after online 
publication. They are given a Digital Object Identifier (DOI), which allows the 
article to be cited and tracked. After publication, the DOI remains valid and can 
continue to be used to cite and access the article. 
OnlineOpen 
 
OnlineOpen is available to authors of primary research articles who wish to make 
their article available to non-subscribers on publication, or whose funding agency 
requires grantees to archive the final version of their article. With OnlineOpen, the 
author, the author's funding agency, or the author's institution pays a fee to ensure 
that the article is made available to non-subscribers upon publication via Wiley 
Online Library, as well as deposited in the funding agency's preferred archive. For 
the full list of terms and conditions, 
seehttp://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms 
 
Any authors wishing to send their paper OnlineOpen will be required to complete 
the payment form available from our website 
at https://onlinelibrary.wiley.com/onlineOpenOrder 
 
Prior to acceptance there is no requirement to inform an Editorial Office that you 
intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen 
articles are treated in the same way as any other article. They go through the 
journal's standard peer-review process and will be accepted or rejected based on 
their own merit. 
Author Services 
Online production tracking is now available for articles through Wiley-Blackwell's 
Author Services. Author Services enables authors to track their article - once it has 
been accepted - through the production process to publication online and in print. 
Authors can check the status of their articles online and choose to receive 
automated e-mails at key stages of production so they do not need to contact the 
Production Editor to check on progress. 
Visit http://authorservices.wiley.com/bauthor/ for more details on online 
production tracking and for a wealth of resources including FAQs and tips on 
article preparation, submission and more. 
Free access to the final PDF offprint of your article will be available via 
author services only.Please therefore sign up for author services if you would like 
to access your article PDF offprint and enjoy the many other benefits the service 
offers. 
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Managing Editor – Carmen Lahiff-Jenkins – carmenl@unimelb.edu.au 
Associate Editor – Professor Peter Rothwell - peter.rothwell@clinical-
neurology.oxford.ac.uk 
Associate Editor – Professor Patrick D Lyden - Lydenp@cshs.org 
Associate Editor – Conrado Estol - cjestol@infovia.com.ar 
Associate Editor – Jong S Kim - jongskim@amc.seoul.kr 
Senior Production Editor - Chrizette Larin - ijs@wiley.com 
 
Writing tips for authors 
These 12 golden rules may assist you with your manuscript. 
 
1. Write and edit to express yourself clearly. Do not use flowery or verbose language. 
2. Always write and edit your text so that everything can be understood. 
3. Always write and edit your work so that nothing can be misunderstood. 
4. Say what you mean to say, clearly and simply. 
5. Use short sentences. 
6. Use short paragraphs. 
7. Use the shortest, simplest words possible. 
8. Write in the active voice. 
9. Avoid unnecessary words. 
10. Use verbs for action. 
11. Avoid clichés and jargon. 
12. If in doubt, leave it out. 
 
